Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 7/20 | 0.48 |
| ▸ | FADS1 | O60427 | 2/20 | 0.45 |
| ▸ | BCL2 | P10415 | 1/20 | 0.44 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | LTA4H | P09960 | 4/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.41 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.41 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2899151 | 1.00 | GRM2 (0.48) | GRM2FADS1BCL2BCL2L1CNR2 | |
| SCHEMBL2893580 | 0.91 | GRM2 (0.48) | GRM2FADS1CNR2LTA4HCYP2A13 | |
| SCHEMBL2893477 | 0.91 | GRM2 (0.48) | GRM2FADS1CNR2LTA4HPRSS12 | |
| SCHEMBL4318416 | 0.91 | GRM2 (0.48) | GRM2FADS1CNR2LTA4HPRSS12 | |
| SCHEMBL2898254 | 0.90 | GRM2 (0.47) | GRM2FADS1CNR2LTA4HPRSS12 | |
| SCHEMBL5474687 | 0.90 | GRM2 (0.49) | GRM2FADS1LTA4HHTR7 | |
| SCHEMBL2893027 | 0.90 | GRM2 (0.49) | GRM2FADS1LTA4HHTR7 | |
| SCHEMBL4323358 | 0.90 | GRM2 (0.47) | GRM2FADS1CNR2LTA4HPRSS12 | |
| SCHEMBL4325296 | 0.88 | GRM2 (0.56) | GRM2FADS1LTA4H | |
| SCHEMBL2896757 | 0.88 | GRM2 (0.56) | GRM2FADS1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816354-B2 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2010-10-19 | — | — | US | claimed |
| US-20090012089-A1 | Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | claimed |
| EP-1994016-A2 | 5-PHENYL-3-BENZYL-OXAZOLIDIN-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | AstraZeneca AB (SE) | 2008-11-26 | — | — | EP | claimed |
| US-20070275966-A1 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | NPS PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | US | claimed |
| WO-2007078523-A2 | 5-PHENYL-3-BENZYL-0XAZ0LIDIN-2-0NE DERIVATIVES AND RELATED COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ASTRAZENECA AB (SE) | 2007-07-12 | — | — | WO | claimed |
| US-7816354-B2 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2010-10-19 | — | — | US | disclosed |
| US-20090012089-A1 | Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | disclosed |
| US-20070275966-A1 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | NPS PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275966-A1 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM2 | GRM2 3/4885FADS1 4353/4885BCL2 4661/4885 |
| US-20090012089-A1 | Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | GRM1, GRIN1, GRM2 | GRM2 3/4885FADS1 4353/4885BCL2 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.